Thursday, February 20, 2014

Kickstarter - Nevermind: A Biofeedback Horror Adventure Game


My friend Arthur turned me on to this Kickstarter campaign to create a biofeedback-enhanced horror adventure game, Nevermind. It uses your stress levels to make the game harder or easier (the more you get stressed, the harder it is). This seems like an amazingly cool way to teach/learn affect regulation.

One exciting facet of Nevermind is its potential to serve as a full-fledged therapeutic tool for those who suffer from issues - mild or severe - relating to stress, anxiety, PTSD, or other similar conditions. Although informal testing results have been promising thus far, we are excited to be in discussion as we speak with researchers who are eager to explore Nevermind's potential impact via rigorous clinical trials.

As a prime example of our passion to create "games that give back", one of our long-term goals is to craft a health-centric version of Nevermind specifically targeted to help actual patients develop tools to manage and ultimately overcome their conditions.
More from Erin Reynolds, the game's creator:
https://www.kickstarter.com/projects/reynoldsphobia/nevermind-a-biofeedback-horror-adventure-game

Nevermind is a biofeedback-enhanced horror adventure game that takes you into the dark and twisted world within the subconscious minds of trauma victims.

As you explore surreal labyrinths and solve the puzzles of the mind, a biofeedback sensor monitors how scared or stressed you become with each passing moment. If you let your fears get the best of you, the game will become harder. If you’re able to calm yourself in the face of terror, the game will be more forgiving.

Nevermind’s goal is to create an unforgettable gameplay experience that also teaches players how to be more aware of their internal responses to stressful situations. If you can learn to control your anxiety within the disturbing realm of Nevermind, just imagine what you can do when it comes to those inevitable stressful moments in the real world . . .
Part of the reason I want to bring this to your attention is that there are only 2 weeks left to get this project funded and they are WAY short of the goal.

If you can help, please do so.

Here is more info on the game:

You'll need an HTML5 capable browser to see this content.

Nevermind is - at its core - an adventure game (in the spirit of classic games like Myst), where you must explore strange worlds and solve puzzles to unlock the terrifying mystery that lurks within each patient’s inner psyche.

In Nevermind, you are a Neuroprober - a unique physician who, through the use of cutting-edge technology, is able to venture into the minds of psychological trauma victims for whom traditional treatment methods have proved ineffective.



As such, each “level” in Nevermind takes place within the surreal subconscious of one of these victims. Your goal is to explore the often dark and twisted world within, solving abstract puzzles as you recover fragments of memories (represented by photographs) surrounding the traumatic event.

Traumatic experiences, especially those left untreated, take their toll in countless ways, often triggering other serious problems as the victim’s subconscious desperately tries to cope. As a result, the patient’s mind doesn’t take kindly to those who attempt to peel back these layers, often prompting it to lash out in terrifying, unexpected ways.

Only the most vigilant of Neuroprobers can withstand the necessary waves of abuse to help their patient find true salvation.

Can you?




*  *  *  *  *



Nevermind started as a 2012 MFA thesis project at USC’s Interactive Media Program, led by industry veteran Erin Reynolds - who returned to academia to pursue new ways to create “positive” games for traditional gaming audiences. After an academic year, Erin and the Nevermind student development team were able to create one fully-functional level - a proof of concept that demonstrated Nevermind’s unique vision and the feasibility of the core technology.

Nevermind has since been featured in numerous festivals and nominated for several awards for innovation and technical achievement, including at IndieCade, Games for Change, SIGGRAPH, Unity Unite Awards, and the Serious Games Showcase and Challenge.




*  *  *  *  *



In light of Nevermind’s critical success, Erin decided to take the plunge - leaving her industry job to commit herself fully to make her dream of a full-featured, commercially viable version of Nevermind a reality. With your support, Nevermind will be the next great horror adventure game - unlike anything you've played before!

BIGGER, BETTER, SCARIER



The final commercial version of Nevermind will contain at least 4 levels (more if we hit our stretch goals!), for 5+ hours of gameplay PLUS the time and resources to feature even higher quality environments to complement a broader variety of new, more terrifying themes and traumas.

Omnivore - Religion in the Public Sphere

From Bookforum's Omnivore blog, here is a collection of recent links on the role of religion in the public sphere, everything from religious pluralism to religious fanaticism to a supposed "global war" on Christianity.

Religion in the Public Sphere

Feb 17 2014 
3:00PM

Luiz Pessoa - "The Cognitive-Emotional Brain" (Brain Science Podcast 106)

Here is another excellent episode of Dr. Ginger Campbell's Brain Science Podcast. In this episode she speaks with Luiz Pessoa, author of The Cognitive-Emotional Brain: From Interactions to Integration.

"The Cognitive-Emotional Brain" (BSP 106)

February 17, 2014
Brain Science Podcast
Hosted by Dr. Ginger Campbell


Luiz Pessoa of the University of Maryland

In The Cognitive-Emotional Brain: From Interactions to Integration neuroscientist Luiz Pessoa argues that emotion and cognition are deeply intertwined throughout many levels of the brain. In a recent interview (BSP 106) Pessoa and I focused on recent discoveries about the amygdala and Thalamus that challenge traditional assumptions about what these structures do. The amygdala processes more than fear (and other negative stimuli) and the Thalamus is more than a mere relay station.

This a fairly technical discussion but Pessoa did a good job of making the material accessible to all listeners. The reason I think these concepts matter is that not only do they challenge overly simplistic notions of how the brain works, but they also challenge our tendency to see emotion and cognition as separate and often opposing processes.

How to get this episode:

FREE: audio mp3 (click to stream, right click to download)
Buy Episode Transcript for $1.
Premium Subscribers now have unlimited access to all old episodes and transcripts.
The most recent 25 episodes of the Brain Science Podcast are still FREE. See the individual show notes for links the audio files.



References and Additional Reading

The Cognitive-Emotional Brain: From Interactions to Integration by Luiz Pessoa
Pessoa L, Adolphs R. (2010) "Emotion processing and the amygdala: from a 'low road' to 'many roads' of evaluating biological significance.” Nature Reviews Neuroscience, 11(11):773-83. doi: 10.1038/nrn2920.
Networks of the Brain by Olaf Sporns
In Search of Memory: The Emergence of a New Science of Mind by Eric R. Kandel (BSP 3)
Beyond Boundaries: The New Neuroscience of Connecting Brains with Machines---and How It Will Change Our Lives by Miguel Nicolelis (BSP 79)
Visit Dr. Pessoa's lab at emotioncognition.org to learn more.

Related Episodes

BSP 11: Emotion
BSP 32: a brief introduction to Neuroanatomy
BSP 65 and BSP 91 are interviews with Jaak Panksepp about the subcortical origins of emotion
I spoke with Olaf Sporns about the Human Connectome and the use of Network Theory in BSP 74 and BSP 103.
BSP 90: a discussion of Self Comes to Mind: Constructing the Conscious Brain by Antonio Damasio.

Announcements

Wednesday, February 19, 2014

What Is Brain Death? (Excellent Explainer)

From Christian Jarrett at Wired, this is a nice explainer on what brain death is and how we can or cannot identify it. As everyone will remember from the Terri Shiavo situation in 2005, the ethics and the emotion around all of this are intense.

What Is Brain Death?


By Christian Jarrett
02.10.14


Image: Flickr / Opensource.com

Brain death is a tragic topic where neuroscience, ethics and philosophy collide. Two recent cases have sent this sensitive and thorny issue once again into the media spotlight.

Last November, 14 weeks into her pregnancy, 33-year-old Marlise Munoz collapsed at home from a suspected pulmonary embolism. The next day doctors declared that she was brain dead. However, against her own and her family’s wishes, John Peter Smith Hospital in Fort Worth Texas chose to maintain Munoz’s body on ventilators because they said they had a legal duty of care to her unborn fetus. On Sunday, January 26, following a successful lawsuit brought by her family, the hospital finally turned off the ventilators.

Meanwhile, teenager Jahi McMath was declared brain dead last December following complications that ensued after a tonsillectomy. In this case, McMath’s hospital wanted to turn off McMath’s artificial life support, but her family resisted this move and she has been transferred to another facility where her body is being maintained by mechanical respirator.

These contrasting cases provide a glimpse into the tragedy and ethical sensitivities surrounding the issue of brain death. Before we go any further, what are your first reactions to the stories? Do you believe that Marlise Munoz was dead after doctors declared her brain dead? What about Jahi McMath?

According to accepted medical and legal criteria, both Munoz and McMath were officially dead from the moment of brain death. The Uniform Determination of Death Act (UDDA) drafted in 1981 is accepted by all 50 US States. It determines that a person is dead if either their cardiovascular functioning has ceased or their brain has irreversibly stopped functioning. The precise methods and criteria for determining brain death vary from hospital to hospital, but the American Academy of Neurology states that three criteria must be fulfilled to confirm the diagnosis: “coma (with a known cause), absence of brainstem reflexes, and apnea [the cessation of breathing without artificial support].” In practice, clinicians will also look for an absence of motor responses (movement) and will rule out any other possible explanations for loss of brain function, such as drugs or hypothermia. Assessment will also be repeated again after several hours. For more details, the NHS website has a description of the diagnostic tests used for brain death in the UK.

The UDDA concept of brain death has its roots in a 1968 definition composed by medics and scholars at Harvard Medical School that outlines how death can be defined in terms of irreversible coma. Steven Laureys (of the Coma Science Group at Liège University Hospital) explains that earlier than that, a pair of French neurologists in 1959 also used the term “coma dépassé” (irretrievable coma) to refer to the same concept.

In contrast to the unequivocal contemporary official medical and legal position on brain death, surveys show widespread misunderstanding among the US public about what the term means. In 2003, in a survey of 1,000 households, James DuBois and T. Schmidt found that 47 percent agreed wrongly that “a person who is declared brain dead by a physician is still alive according to the law.” In 2004, a survey of 1,351 residents of Ohio found that 28 percent believed that brain dead people can hear. Yet another study, from 2003, found that only 16 percent of 403 surveyed families equated brain death with death.

This confusion is reflected in recent media coverage of the cases of Munoz and McMath. On January 26, reporting on the case of Marlise Munoz, the BBC stated: “A brain dead woman kept alive by a hospital in Texas because she was pregnant has been taken off life support [emphasis added].” In fact Munoz was not “kept alive” by the hospital – she was legally dead the moment that doctors determined that she was brain dead. Or consider an essay in American Thinker published on January 28: “Jahi McMath is alive [emphasis added]” declares its headline. And finally, from just a few days ago in Hollywood Life: “Brain dead woman to be kept alive until baby’s birth [emphasis added].”

These deviations from accepted medical understanding are not new or unusual. In an article published last year, Ariane Daoust and Eric Racine surveyed media coverage of brain death in US and Canadian newspapers between 2005 and 2009. They found few accurate definitions of brain death, together with many contradictory and colloquial uses of the term. Not only is “brain dead” used as a slang derogatory term for stupid politicians and celebrities, it’s also used erroneously to refer to people in a persistent vegetative state (PVS is characterised by a complete lack of awareness, but unlike brain death, this is sometimes potentially reversible, and some brain activity remains including brainstem function; Terri Schiavo was diagnosed as being PVS). Daoust and Racine also cited examples of news reports that implied a person could die a second time – once from brain death, and then a second death after life support is removed. For example, this is from The New York Times in 2005: “That evening Mrs. Cregan was declared brain-dead. The family had her respirator disconnected the next morning, and she died almost immediately.”

Surveys show that even medical professionals often lack understanding of the concept. In 2012, for example, a Spanish survey of graduating medical students found that only two-thirds believed that brain death is the same as death. Longer ago, in 1989, Youngner et al surveyed 195 US physicians and nurses and found that only 38 percent correctly understood the legal and medical criteria for death. In an overview of surveys of the public and medical personnel, James DuBois and colleagues in 2006 concluded that “studies consistently show that the general public and some medical personnel are inadequately familiar with the legal and medical status of brain death.”

Perhaps the most alarming example of misunderstanding of brain death by a medical professional comes from a 2007 paper by Professor of Medical Ethics Robert Truog (pdf). He describes the time that Dr. Sanjay Gupta (a neurosurgeon and Senior Medical Correspondent for CNN) appeared on Larry King in 2005 to discuss the tragic case of Susan Torres, another pregnant woman declared brain dead. “Well, you know, a dead person really means that the heart is no longer beating,” Gupta said. “I mean, that’s going to be the strict definition of it […] people do draw a distinction between brain dead and dead.” Here, in front of a massive mainstream audience, Dr. Gupta profoundly misrepresented the medical and legal facts around the criteria for death.

It is easy to understand why there is so much confusion. Many people implicitly associate life with breathing and heart function, and to see a person breathing (albeit with artificial support) and to be told they are in fact dead can be difficult to comprehend. The ability after brain death to carry a fetus, for wounds to heal, and for sexual maturation to occur also adds to many people’s incomprehension at the notion that brain dead means dead. But for those more persuaded by the idea of death as irrevocably linked, not with brain function, but with the end of heart and lung activity, consider this unpleasant thought experiment (borrowed from LiPuma and DeMarco). If a decapitated person’s body could be maintained on life support – with beating heart and circulating, oxygenated blood – would that person still be “alive” without their brain? And consider the converse – the classic “brain in a vat”. Would a conscious, thinking brain, sustained this way, though it had no breath and no beating heart, be considered dead? Surely not. Such unpalatable thought experiments demonstrate how brain death can actually be a more compelling marker of end of life than any perspective that focuses solely on bodily function.

Let’s be clear – there is continuing expert and public debate and controversy around how to define death, including brain death (to give you a taster, scholarly articles published over the last decade include “The death of whole-brain death” and “The incoherence of determining death by neurological criteria“). It is right that this debate and discussion continues. However, it’s also important that the public understand the existing consensus that is founded on the latest medical evidence and deliberation – that brain death means death. It’s not a preliminary or unfinished form of death. It’s not a persistent vegetative state. It is final. It is death. Families and medical professionals caring for brain dead patients are involved in terribly difficult decisions about organ donation and it is especially crucial that they know what the current medical and legal consensus is, and that they understand brain death means a permanent end of the person’s mental processing and consciousness, and therefore the end of life. Unsurprisingly, surveys show that people’s decisions about organ donation are affected by their understanding of what brain death means – people who think that brain death isn’t equivalent to death are less likely to agree to donation.

Of course, some people will have personal, spiritual or religious beliefs that contradict the current medical and legal position on brain death (such is the case with McMath’s family), and respect and sensitivity is important in these cases. Note, however, that both mainstream Judaism and Islam have accepted the concept of brain death. And, according to Steven Laureys writing in 2005, the Catholic Church has also stated that “the moment of death is not a matter for the church to resolve.”

I hope I have presented a fair and clear explanation of the current US medical and legal consensus on brain death. This is a tragic and sensitive issue and my heart goes out to the families of Munoz and McMath and others in similar situations.

Homepage image: Joachim Böttger via Ars Electronica/Flickr


Christian Jarrett is a cognitive neuroscientist turned science writer. He’s editor of The British Psychological Society’s Research Digest blog, staff writer on their magazine The Psychologist, and a columnist for 99U. He’s also author of The Rough Guide to Psychology, editor of 30-Second Psychology, and co-author of This Book Has Issues. His next book due in 2014 is Great Myths of the Brain.

Read more by Christian Jarrett

Follow @Psych_Writer on Twitter.

Jerome Groopman - Marijuana: The High and the Low


From The New York Review of Books, Jerome Groopman reviews A New Leaf: The End of Cannabis Prohibition, and he also adds a pretty solid background on the use of cannabis in history. This is an excellent overview and review of the book and the issues around making medical marijuana more accessible.

Marijuana: The High and the Low

Jerome Groopman
February 20, 2014 Issue

A New Leaf: The End of Cannabis Prohibition
by Alyson Martin and Nushin Rashidian
New Press, 264 pp., $17.95 (paper)

Jeff Chiu/AP Images Medical marijuana patient Kevin Brown at the Apothecarium, a medical cannabis dispensary in San Francisco, December 2011

In the summer of 2006, a young scientist from Israel joined my laboratory. He came to learn how viruses attack cells, a major focus of my research program. And I looked forward to drawing on his expertise in an emerging area of science that intrigued me: the biological effects of cannabinoids, the active chemical compounds in the marijuana plant. The Israeli researcher had trained at Jerusalem’s Hebrew University with Professor Raphael Mechoulam, a chemist credited with the discovery in 1964 of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in marijuana. Mechoulam later characterized cannabidiol (CBD), a related substance plentiful in the plant, as distinct from THC in that it had no discernible effects on mood, perception, wakefulness, or appetite.1

The work of the young scientist proved productive. In short order, he tested the effects of several cannabinoids on a herpes virus that promotes the development of Kaposi’s sarcoma, a disfiguring and sometimes fatal tumor among people with impaired immunity, like those with AIDS. It turned out that CBD, the plentiful, nonpsychoactive compound, could switch off the malignant effects of the virus.2 Scientists in my department also found that cannabinoids could alter how white blood cells migrated in response to physiological stimuli, a key aspect of immune defense; other research teams found that THC inhibited the growth and spread of lung cancer and CBD of breast cancer in laboratory models.3 Clearly, chemicals in the plant could have diverse and potent effects on normal and malignant cells.

But what I found most fascinating was that we have a natural or “endogenous” cannabinoid system. In 1988, researchers identified a specific docking site, or receptor, on the surface of cells in the brain that bound THC. This first receptor was termed cannabinoid receptor 1, or CB1.4 Five years later, a second receptor for cannabinoids, CB2, was found.5 This latter docking protein was less plentiful in the central nervous system but richly present on white blood cells. Again, it was Raphael Mechoulam who discovered the first endogenous cannabinoid, a fatty acid in the brain, which he termed “anandamide.” (The name is derived from the Sanskrit word ananda, which means “bliss.”) When anandamide attached to CB1 it triggered a cascade of biochemical changes within our neurons.6

Other endogenous cannabinoids were later identified. This makes evolutionary sense, since the CB1 and CB2 receptors would not be present on our cells if we did not normally make molecules to dock on them. The physiological ramifications of endogenous cannabinoids appeared quite broad; their most impressive effects were related to perception of and response to pain.

CANNABIS is one of the oldest psychotropic drugs in continuous use. Archaeologists have discovered it in digs in Asia that date to the Neolithic period, around 4000 BCE. The most common species of the plant is Cannabis sativa, found in both tropical and temperate climates. Marijuana is a Mexican term that first referred to cheap tobacco and now denotes the dried leaves and flowers of the hemp plant. Hashish is Arabic for Indian hemp and refers to its viscous resin. An emperor of China, Shen Nung, also the discoverer of tea and ephedrine, is held to be among the first to report on therapeutic uses of cannabis in a medicinal compendium that dates to 2737 BCE. In 1839, William O’Shaughnessy, a British doctor working in India, published a paper on cannabis as an analgesic and appetite stimulant that also tempered nausea, relaxed muscles, and might ameliorate epileptic seizures. His observations led to widespread medical use of cannabis in the United Kingdom; it was prescribed to Queen Victoria for relief of menstrual discomfort.7

The cannabis plant contains some 460 compounds, including more than 60 cannabinoids. THC, the key psychoactive substance in marijuana, has increased from about 1–5 percent to as much as 10–15 percent in cultivated plants since the 1960s. When herbal cannabis is smoked, some 20 to 50 percent of the THC is absorbed via the lungs. When herbal cannabis is eaten, less THC reaches the brain because it is metabolized as it passes from the gut through the liver. THC accumulates in fatty tissues, from which it is slowly released, and acts primarily on CB1 receptors in the brain’s mesolimbic dopamine system, which is believed to contribute to the positive reinforcing and rewarding effects of the drug.8

While smoking or eating cannabis typically results in the user’s feeling “high,” with a relaxed, euphoric sense as anxiety and alertness decrease, some first-time users, as well as individuals who have psychological problems, can experience dysphoria, fear, and panic. Typically, when high on marijuana, there is an increased sense of sociability, although among those who have a dysphoric reaction, there can be sharp social withdrawal. Perception of time is altered, generally with perceived time faster than clock time; spatial perception also may change, and colors may seem brighter and music more resonant. High doses of cannabis can result in hallucinations, which may account for its religious use in some cultures. Yet unlike opioids, there are no reported cases of death due to a THC overdose, probably because cannabinoids do not inhibit our respiratory drive, which would result in asphyxiation. Among regular users, abstinence from marijuana can cause an uncomfortable or distressing withdrawal syndrome.

In 2008 the World Health Organization published a Mental Health Survey of 54,068 persons age sixteen and older in seventeen nations. On the basis of this survey, cannabis was found to have been used at least once by some 160 million people between the ages of fifteen and sixty-five; reported use was lowest in the People’s Republic of China, 0.3 percent, and highest in the United States, 42.4 percent, with New Zealand close behind.9

Despite such widespread use, cannabis is illegal in most countries. Harry J. Anslinger, a prominent prohibitionist, successfully lobbied Congress to pass the Marihuana Tax Act in 1937, making access to the plant costly. Anslinger was the head of the Federal Bureau of Narcotics and presented cannabis use to the public as an unalloyed danger, resulting in “reefer madness.” The American Medical Association opposed the Marihuana Tax Act, fearing that it would limit medicinal study and potential prescription of the plant. Long a part of the United States Pharmacopeia, a compendium that set standards for medicines and foods, cannabis was removed in 1942.

In 1970, Congress enacted the Controlled Substances Act, classifying marijuana along with heroin as a Schedule I drug. Drugs in this category have a proven potential for abuse and no medical value. (Opium, the source of morphine, and amphetamines are Schedule II drugs, classified as less dangerous despite their potent addictive properties.) Soon thereafter, President Nixon launched the “war on drugs,” and in 1986, President Reagan signed the Anti-Drug Abuse Act, which mandated prison sentences without parole for offenders convicted of possession and sale of all illegal drugs, including marijuana.

THE STUDY of cannabinoids, both those derived from plant sources as well as the endocannabinoids that exist naturally within our body, is now an extensive enterprise that spans the globe and links numerous scientists in both academic centers and pharmaceutical companies.

Mitch Earleywine, a prominent researcher on drugs and addiction at SUNY Albany, observed how results from current studies on marijuana are akin to Rorschach blots. “People purportedly see these ambiguous pictures in a way that reveals more about them than the ink.” Many who make public policy or are associated with interest groups, he contends, may respond to marijuana research according to the views of these groups: their interpretations say more about their own biases than about the actual data. For example, prohibitionists contend that THC often appears in the blood of people involved in auto accidents; yet they omit the fact that most of these people also had been drinking alcohol. Antiprohibitionists cite research that showed no sign of memory problems in chronic marijuana smokers; but they do not mention that the cognitive tests were so easy that even an impaired person could perform them.

Two recent reviews avoid such biases and critically examine data from more than a hundred randomized placebo-controlled clinical trials involving some 6,100 patients with a variety of medical conditions.10 Marijuana appears useful in treating anorexia, nausea and vomiting, glaucoma, irritable bowel disease, muscle spasticity, multiple sclerosis, symptoms of amyotropic lateral sclerosis (Lou Gehrig’s disease), epilepsy, and Tourette’s syndrome. (Recent clinical trials confirm many of the claims of Emperor Shen Nung and Dr. O’Shaughnessy.) Despite findings from experiments in my laboratory and others, its anticancer effects in patients are more uncertain and neither THC nor CBD is a proven antineoplastic agent, i.e., effective in treating abnormal growth of tissue.

Judy Foreman, an accomplished medical journalist, devotes a chapter to marijuana in her recent book A Nation in Pain: Healing Our Biggest Health Problem.11 She judiciously reviews the data on the risks and benefits of marijuana as a therapy for medical conditions marked by pain, highlighting where it appears ameliorative, where it falls short, and where there is lack of clarity about its value. Foreman writes:
To put it bluntly, marijuana works. Not dazzlingly, but about as well as opioids. That is, it can reduce chronic pain by more than 30 percent. And with fewer serious side effects. To be sure, some researchers think it’s too soon to declare marijuana and synthetic cannabinoids a first-line treatment for pain, arguing that other drugs should be tried first. But that may be too cautious a view.
Ultimately, marijuana may be used in conjunction with opioids like morphine to allow for lower doses and fewer of the side effects of the opioid family of analgesics. While chronic pain seems amenable to amelioration by marijuana, its impact on reducing acute pain, such as after surgery, is minimal.

How do cannabinoids reduce pain? Some of the benefit appears to result from cognitive dissociation: you realize that pain is present, but don’t respond to it emotionally. If you are able to detach yourself from pain in that way, there is less suffering.

EVERY therapy, whether a drug or a procedure, involves a tradeoff of benefits versus risks. Perhaps the most controversial and important concern around cannabinoids is whether they increase the risk of psychoses like schizophrenia. This question is most germane for adolescents and young adults. A number of studies reviewed the health records of young people in Sweden, New Zealand, and Holland who reported cannabis use, as compared to the records of those who did not. A combined or metaanalysis of results from nearly three dozen such studies linked cannabis use to later development of schizophrenia and other psychosis.12

The limitation of such observational studies is that they may suggest an association but in no way prove a causal link. Indeed, the medical literature is littered with observational studies that were taken as meaningful but later overturned when randomized placebo-controlled trials were conducted. Here the Women’s Health Initiative comes to mind. This was a randomized study, using placebos as controls, that reversed some four decades of thinking about the alleged benefits of hormonal replacement therapy among postmenopausal women in preventing dementia and heart disease. No one is likely to conduct a randomized controlled trial of thousands of teenagers, assigning one group to smoke or ingest cannabis and the other group to receive placebos. The issue of marijuana as a cofactor in the development of schizophrenia and other psychosis will therefore remain unresolved.

What is clear is that cannabis impairs cognition and psychomotor responses. Numerous studies show that it lengthens a person’s reaction time and impairs his or her attention, concentration, short-term memory, and assessment of risks. These changes in psychomotor performance can last longer than the feeling of being high. Trials with licensed pilots found that marijuana impaired performance on a flight simulator for up to twenty-four hours.13 Further, most of the pilots were unaware that their performance was still impaired a day later. Several studies demonstrate associations between cannabis and collisions: drivers who use it are estimated to be some two to seven times more likely to be responsible for accidents compared to drivers not using drugs or alcohol.14

The American Psychiatric Association, in the new DSM-5, has defined a diagnosis of “cannabis use disorder.” These people had a repeated pattern of use with harmful consequences, such as inability to fulfill major responsibilities at work and persistent social problems at home. Both the DSM-5 and the World Health Organization’s International Classification of Diseases 10th edition (ICD-10) also include a list of possible symptoms of withdrawal from using cannabis: significant fatigue, sleepiness, psychomotor retardation, anxiety, and depression.15 Yet there is fierce argument about whether marijuana is addictive. Proponents of cannabis doubt that it can cause true addiction, a physiological condition with compulsive craving and use despite harm; they argue that any dependence is less significant than that seen with alcohol. Opponents of cannabis use, particularly those from the National Institutes of Health, affirm both dependence and addiction as real risks, although at a much lower percentage than that seen with cocaine or heroin.16

A New Leaf is a detailed account of the history of the regulation of cannabis, presenting in a blow-by-blow manner the legal and political battles around its prohibition. It opens on a celebratory note, with the legalization of marijuana for recreational use in two states:
Another prohibition is ending. On November 6, 2012, voters in Colorado and Washington were the first in the world to successfully challenge nearly a century of bad policy and misconceptions about cannabis.
In downtown Seattle, the Hotel Ändra was dressed white and blue, the team colors of Washington State’s…campaign….
Around 7 p.m., the owner of one of the largest and most successful medical cannabis dispensaries in the country arrived. Steve DeAngelo was unmistakable even in a crowd, with his signature long, tight pigtail braids and dark fedora…. Earlier that year, he was the star of his own Discovery Channel show, Weed Wars. His two Harborside Health Centers are in the Bay Area, but he had a soft spot for Seattle. Just a few months before, he had spoken at Seattle’s well-known Hempfest, attended by tens of thousands each year. “I’ve been working on this issue for my entire life…. And I know tonight…that there’s going to be a whole lot of angels dancing in heaven,” DeAngelo said, his eyes flooding.
The authors describe a similar scene in Denver:
Brian Vincente, a lawyer who advocated for medical cannabis in Colorado for nearly a decade,… took the stage. “Tonight we made history. This is something you’re going to tell your kids about,” Vincente said. “Marijuana prohibition started in 1937. The first person arrested was in Colorado.” The crowd booed. “Colorado fucking turned this thing around tonight.” And with the f-word came gaiety.
These successes resulted from a unique effort joining groups from the ends of the political spectrum:
The support of conservative Republicans and Libertarians was as important to the Colorado…campaign as that of Democrats and liberals…. The swing state of Colorado, birthplace of the Libertarian party, is decidedly purple. The Libertarian Party of Colorado emphatically endorsed Amendment 64 in May, for example, while the Colorado Democratic Party offered support but stopped short of an endorsement. The Republican Liberty Caucus of Colorado also endorsed the amendment because prohibition is “inconsistent with Republican values,” which call for more “personal responsibility” and less “federal overreach.”
RECENT articles in The New Yorker17 and The Nation18 describe in a succinct and focused way the political terrain around cannabis legalization for medicinal or recreational use in the United States. The New Yorker article features Professor Mark Kleiman, a drug policy expert at the University of California, Los Angeles, who sees legalization through the perspective of a scientist, who regards it as a kind of ongoing experiment. Legalization will test a group of hypotheses about public policy, and he suspends conclusions until more data are available.

As with every social initiative, there could be negative effects and Kleiman advocates close monitoring of excessive use among adolescents and of driving under the influence when cannabis is legal for recreational use. He “appears,” according to the New Yorker article, “to derive grim pleasure from informing politicians that they have underestimated the complexity of a problem.” One major concern is that when legal marijuana goes on sale in Washington State this spring, the current black market will not disappear; rather, legal over-the-counter marijuana will be competing with illicit sources. Kleiman argues that to support the legal market, there should be even greater law enforcement pressure on those who do not respect the rules. In Washington, few in government wanted to hear such a proposal.

Similarly, Kleiman is not confident that alcohol will become less appealing as marijuana is made available. While he acknowledges that alcohol is the greater danger of the two, he raises the possibility that cannabis will be used to complement drinking. Finally, he says that in the “Manichaean world of politics,” the pendulum may swing from marijuana as illegal—with sale or use of it causing imprisonment—to “going all the way to ‘We should sell it like cornflakes.’”

Unlike the cautious New Yorker piece, the articles in The Nation offer a robust endorsement of legalization. The cover of the magazine displays a photograph of a young Barack Obama flashing the V for victory sign with friends in high school clustered around the logo of the “Choom Gang.” An accompanying editorial by Katrina vanden Heuvel notes that recent presidents, including Bill Clinton, George W. Bush, and Barack Obama, all “have more or less owned up to breaking America’s drug laws” through possession or use of cannabis; if they had been observed by the police, they might well have been incarcerated, with no hope of a career leading to the White House. A New Leaf emphasizes the risks of arrest for possession. Racial discrimination, with disproportionate numbers of African-Americans arrested, is one ugly reality of prohibition:
While cannabis users who are arrested are not often sent to prison, there are still more than twenty thousand people incarcerated for mere possession. According to a comprehensive 2013 report released by the ACLU, between 2001 and 2010 more than 8 million cannabis arrests were made in the United States (88 percent for possession), and the possession enforcement alone cost more than $3.6 million in 2010.  
Across the country, blacks are nearly four times more likely than whites to be arrested for cannabis possession, despite comparable rates of use; in some counties that number increases from four to thirty. Finally, 62 percent of those arrested are twenty-four or younger, which means their arrest records will follow them throughout adulthood.
All of these wasted hours, dollars, and arrests are a distraction from hard drug use and trafficking:
Again, when cannabis—which accounts for 80 percent of all illegal substance use in the United States—is removed from the drug war picture, the country can more effectively discuss and implement a new and more fitting public health approach for the remaining hard drugs.
SEVERAL years ago, I consulted on the case of a young woman with anemia. Her internist had made an exhaustive evaluation of her condition but had found no cause for it. The patient had been under a great deal of stress at work, and when I asked how she dealt with this, she said she had been smoking marijuana every night. A bone marrow examination showed reduced numbers of cells, not severe enough to be classified as aplastic anemia, but certainly abnormal in a woman in her twenties. The numerous components of cannabis are not known to be toxic to blood cells; marijuana smoking has not been reported as a cause of anemia. But I recalled that some of the illicit crops had been sprayed with toxins that might have deleterious effects on blood cell development.

So together we decided that she would suspend smoking, and over a period of months her anemia was resolved. A subsequent bone marrow examination showed full restoration of normal blood cell numbers. This was not definitive proof, but it certainly suggested that something in the grass she got from a dealer was the potential culprit. If there is not adequate oversight of the marijuana on sale, those seeking street cannabis could be exposed to dangerous contaminants.

In a forthcoming book, Weed Land, Peter Hecht, a journalist at The Sacramento Bee, charts the evolution of California’s medical marijuana law, the first in the nation.19 Much of the momentum behind its passage came from a joining of forces between AIDS activists and academic physicians like Donald Abrams at San Francisco General Hospital, who demonstrated the clinical benefits of augmented appetite and relief of pain in patients with cachexia from HIV. Medical marijuana, now legal in twenty states and the District of Columbia, is regulated like a supplement rather than a drug. There is no standardization of optimal amounts of psychoactive THC and nonpsychoactive CBD, although they must be free of toxins. (A British company, GW Pharmaceuticals, makes Sativex, an oral spray containing extracts of two standardized cannabis strains that are mixed to give exact doses of THC and CBD. Sativex was approved in several countries, but not in the United States.)

For a physician like myself prescribing a therapy, this is an uncomfortable situation, because a prescription should be exact in specifying how much drug is delivered. Further, side effects may occur in patients taking multiple other medications, due to so-called “drug-drug interactions.” Such interactions have not been well studied with THC and CBD, in part because of the restriction of access to the plant for the clinical research community. Scientists in my laboratory studied pure chemicals, THC and CBD, under strict federal oversight; we purchased the cannabinoids from chemical companies that used quality control. As Martin and Rashidian note, clinical study of the plant itself, with its scores of active chemicals, is another matter:
The federal government has imposed additional and unique restrictions on cannabis research, with little rationale—beyond politics. The federal government has enabled only one institution, the University of Mississippi, to legally grow cannabis for research on its behalf, although it is free to award additional and alternative contracts. And cannabis is the only research substance for which the government is the sole supplier. For a scientist to receive cannabis from the federal farm at the University of Mississippi, a trifecta of approvals…must be obtained from the FDA, DEA, and a Public Health Service panel.
Perhaps as states legalize marijuana, this barrier to research will be lowered, as it was for stem cell research, once restricted by federal law. And as more studies are conducted on marijuana for medical or recreational uses, opponents and enthusiasts may both discover that they were neither entirely right nor entirely wrong.


Notes


1. Mohamed Ben Amar, “Cannabinoids in Medicine: A Review of Their Therapeutic Potential,” Journal of Ethno-pharmacology, Vol. 105 (2006); Arno Hazekamp and Franjo Grotenhermen, “Review on Clinical Studies with Cannabis and Cannabinoids 2005–2009,” Cannabinoids, Vol. 5 (2010).

2. Y. Maor, J. Yu, P.M. Kuzontkoski, B.J. Dezube, X. Zhang, and J.E. Groopman, “Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma–Associated Herpesvirus-Infected Endothelium,” Genes & Cancer, Vol. 3, No. 7–8 (2012); X. Zhang, J.F. Wang, G. Kunos, and J.E. Groopman, “Cannabinoid Modulation of Kaposi’s Sarcoma–Associated Herpesvirus Infection and Transformation,” Cancer Research, Vol. 67, No. 15 (August 1, 2007).

3. S. Ghosh, A. Preet, J.E. Groopman, and R.K. Gaju, “Cannabinoid Receptor CB 2 Modulates the CXCL 12/ CXCR 4-Mediated Chemotaxis of T Lymphocytes,” Molecular Immunology, Vol. 43 (2006); A. Preet, R.K. Ganju, and J.E. Groopman, “∆ 9 -Tetrahydrocannabinol Inhibits Epithelial Growth Factor–Induced Lung Cancer Cell Migration in Vitro as Well as Its Growth and Metastasis in Vivo,” Oncogene, Vol. 27 (2008); X. Zhang, Y. Maor, J.F. Wang, G. Kunos, and J.E. Groopman, “Endocannabinoid-like N-arachidonoyl Serine Is a Novel Pro-angiogenic Mediator,” British Journal of Pharmacology, Vol. 160 (2010); A. Preet, Z. Qamri, M. Nasser, A. Prasad, K. Shilo, X. Zou, J.E. Groopman, and R. Ganju, “Cannabinoid Receptors, CB 1 and CB 2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis,” Cancer Prevention Research, Vol. 4 (2011); A. Shrivastava, P.M. Kuzontkoski, J.E. Groopman, and A. Prasad, “Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-Talk Between Apoptosis and Autophagy,” Molecular Cancer Therapeutics, Vol. 10 (2011).

4. W.A. Devane, F.A. Dysarz III, M.R. Johnson, L.S. Melvin, and A.C. Howlett, “Determination and Characterization of a Cannabinoid Receptor in Rat Brain,” Molecular Pharmacology, Vol. 34 (November 1, 1988).

5. S. Munro, K.L. Thomas, and M. Abu-Shaar, “Molecular Characterization of a Peripheral Receptor for Cannabinoids,” Nature, Vol. 365 (1993).

6. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin, “Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor,” Science, Vol. 258 (December 18, 1992).

7. D. Baker, G. Pryce, G. Giovannoni, and A.J. Thompson, “The Therapeutic Potential of Cannabis,” Lancet Neurology, Vol. 2 (May 2003).

8. Mitch Earleywine, Understanding Marijuana: A New Look at the Scientific Evidence (Oxford University Press, 2002).

9. L. Degenhardt, W.T. Chiu, N. Sampson, et al., “Toward a Global View of Alcohol, Tobacco, Cannabis, and Cocaine Use: Findings from the WHO World Mental Health Surveys,” PLoS Medicine, Vol. 5 (July 2008).

10. See Amar, “Cannabinoids in Medicine: A Review of Their Therapeutic Potential,” and Hazekamp and Grotenhermen, “Review on Clinical Studies with Cannabis and Cannabinoids 2005–2009.”

11. Oxford University Press, 2014

12. M. Large, S. Sharma, M.T. Compton, T. Slade, O. Nielssen, “Cannabis Use and Earlier Onset of Psychosis,” Archives of General Psychiatry, Vol. 68, No. 6 (2011).

13. V.O. Leirer, J.A. Yesavage, and D.G. Morrow, “Marijuana Carry-Over Effects on Aircraft Pilot Performance,” Aviation, Space, and Environmental Medicine, Vol. 62, No. 3 (1991); D.G. Newman (Australian Government, Australian Transport Safety Bureau), “Cannabis and Its Effects on Pilot Performance and Flight Safety: A Review” (2004).

14. M. Asbridge, J.A. Hayden, and J.L. Cartwright, “Acute Cannabis Consumption and Motor Vehicle Collision Risk: Systematic Review of Observational Studies,” BMJ, Vol. 344, No. 14 (2012).

15. D.S. Hasin, K.M. Keyes, D. Alderson et al., “Cannabis Withdrawal in the United States: Results from NESARC,” Journal of Clinical Psychiatry, Vol. 69, No. 9 (2008).

16. See Baker et al., “The Therapeutic Potential of Cannabis,” and Foreman, A Nation in Pain.

17. Patrick Radden Keefe, “Buzzkill,” The New Yorker, November 18, 2013.

18. Katrina vanden Heuvel, “Why It’s Always Been Time to Legalize Pot,” and other articles in The Nation ’s “Special Issue: Marijuana Wars,” November 18, 2013.

19. Peter Hecht, Weed Land: Inside America’s Marijuana Epicenter and How Pot Went Legit (University of California Press, May 2014).

Matter, Makers, Microbiomes, and Generation M (via the P2P Foundation)

 

From Michel Bauwens at the P2P Foundation blog, this is an interesting "manifesto" for a Generation M (the first generation of the 21st Century), as in Matter, Makers, and Microbiomes. As is true of all manifesto's, it comes off as pretty damn idealistic - but considering the world we live in right now, a little idealism can't be a bad thing.

Matter, Makers, Microbiomes, and Generation M

Michel Bauwens
14th February 2014

Interesting manifesto for the (bio) maker generation:

* Article / Manifesto: Generation M. Matter, Makers, Microbiomes::Compost for Gaia. By Dimitris Papadopoulos.

“1. Language, information and the virtual space were distinctive features of the previous generation. Craft, matter and the fusion of the digital and the material are defining generation M, the first generation of the 21st century.

2. Generation M makes stuff. Not through mass production but by tweaking and expanding the capabilities of existing things and processes. The maker’s craft: tinkering, stretching, knitting, inventing, weaving, recombining.

3. Making starts from what is there. Intensive recycling. Immediate caring. Generation M lives in a terraformed earth: climate change, toxic environments, the 6th extinction, soil degradation, energy crises, increasing enclosures of the naturecultural commons. It encounters these harmful life thresholds with responsibility to the limits of productionism. Production does not characterise generation M’s mode of life — co-existence does. Response-able terraformation. We make as we co-exist in ecological spaces.

4. Generation M is all about collaborations that create the very material conditions we live in. But these are neither collaborations between individuals or minds, nor social cooperation. These are collaborations between diverse material forces of living matter and abiotic matter. Beyond the masculine and able-bodied logic of expansive productionism making is, literally, about creating and maintaining relations and exchanges in proximity (not necessarily spatial or temporal promixity).

5. It is about making life with other beings and material formations. The organisational principle of this mode of existence is neither the singular subject nor the network nor the pack but the communities of species and things. The microbiome is a manifestation of this principle: to be invaded and to let oneself be invaded by bacterial communities, to become a host and a recipient simultaneously—co-exist, exchange, change—in order to form a sustainable life. From the sterile environments of network society, cognitive capitalism and the knowledge economy that characterised the previous generation to the wet, contagious involutions of interspecies and multi-material communities.

6. Making is uncomfortable with both the mass production of the Fordist era and the lean production of the post-Fordist period. We move from industrialism through immaterial labour to embodied manufacturing; from the factory through the social factory to communal production.

7. Generation M’s work is self-organised and community managed. Post- Fordism is characterised by the flexibilisation and precarisation of work. Precarity is institutionalized in the public and private sectors and presented as unavoidable for society and economy. Responses that oppose precarity (as trade unions occasionally do) or fantasize zero work (70s-80s social movements and their revivals) become irrelevant as work in the M age becomes inextricable from our very ontological make-up.

8. The digital and the material fuse. The digital alone is no longer the drive of social life and innovation. There is no opposition between matter and code. Everyday objects are digitalized and interlinked within the web of things.

9. Technoscience is more than a source of knowledge and innovation. It is the immediate and vital environment which the first generation of the 21st century inhabits. The participation in and the appropriation of technoscience is essential for Generation M’s self-organised and community managed work.

10. Financialisation, algorithmic valuation and the virtualisation of money served as the engines for strengthening the trembling economies of the Global North in the previous decades. Together with the creative, digital and service industries their role is decreasing as the main drivers of the economy. Deep social transformation unfolds as all these sectors are gradually diffused into micro-manufacturing.

11. Various social movements prepared the ascendance of generation M by defending social rights, expanding the commons, creating open software/open science/open hardware, by fighting for a real democratic, equal and just access to material and symbolic resources against racist, sexual, gender and geo-political exclusions.

12. Social movements in the M age make a step further. They will not only act politically and institutionally to defend the commons but immerse in immediate, real, material practices for commoning life and the environment. A new cycle of social antagonism is emerging, one that unfolds through molecules, tissues, composite materials, energy flows, cross-species love, mundane caring for others we live with.

13. This is ecological transversality—the transfer of substances, processes and practices across disparate material registers and communities of life. Today, we are stuck in the process of translation. As much as translation is necessary it captures only a small part of the communication between disparate communities. Rather than through translation, communication happens through involuntary infections and contingent permutations between organisms or substances that attract each other.

14. Making is always located in mundane interactions and encounters across divergent ecologies. This is the unintentional gift economy of matter and cross-species action. The maker’s worlds always contaminate each other laterally. Drifting matter. Stuck in translation, we believe in the one universal world of communication and value. This is the underlying trope of the anthropocene narrative—the ultimate popular story of ecological guilt and redemption—: We terraformed Earth! We have created this mess! Another world is possible. Another world is here: one that challenges the oppressive universalism of the maker-of-one-world. Generation M inverts terraformation: neither the making of one single ontology nor the making of multiple ontologies, but grounded making: the non-anthropocentric making of alter-ontologies.

15. Making : composting. Everyday life as something that can be composted, as something that has the capacity in the right conditions to change its ontological constitution in ways that avoid erosion, toxicity, and acidity. To compost is to sustain an environment that allows mixtures of organic residues to decompose and transform into new organic compounds for nurturing the soil and growing plants; to compost everyday life means to contribute to the emergence of new mixtures of social, biotic and inorganic materials that nurture liveable worlds.

16. Surveillance and control of the virtual space (think NSA) is destructive and oppressing, but a similar type of surveillance on the material level would be truly terrifying. The direct surveillance of bodies and ecologies on a chemical-molecular level will cause unbelievable pain and install totalitarian control. Generation M is, consciously or subconsciously, aware of this danger. The hope is in acting autonomously to protect our own bodies and the eco-bodies from the malignant growth of material policing.

17. Some of the infrastructures of generation M’s autonomy are already under construction. Justice engrained into the material constitution of our lives. Striving for institutional justice is not enough. Justice needs to be fought for on the level of matter and through close alliances between engaged groups of animals and plants, committed groups of humans and accessible material objects.

18. The hype of human-nonhuman mixtures cannot sustain the commitment to material justice. Posthumanism and actor networks are not good enough for this. An autonomous political posthumanism emerges in the infrastructures of the M era: calculating interdependences, knowing and naming one’s allies, building communities of justice, that is action groups of committed humans and engaged non-human others.

19. Generation M is not a ‘post’ generation. Generation M is in the making. Compost. Generation M does not announce something definite and new; it is the first generation that makes itself — literally. Anything is possible within the situated constraints of our material interdependences.

20. M for matter, M for manufacture, M for material, M for making, M for makers, M for microbiomes.

21. M for Gaia.”

Bio
Dimitris Papadopoulos is a Reader in Sociology and Organisation and Director of the PhD Programme in the School of Management, University of Leicester.

His work in cultural studies of science and technology, politics and social theory, labour and transnational migration has been published in various journals and in several monographs, including Escape Routes, Control and Subversion in the 21st Century (Pluto Press 2008), Analysing Everyday Experience: Social Research and Political Change (Palgrave 2006), and Lev Vygotsky: Work and Reception (Campus 1999/Lehmanns 2010). He is currently completing Crafting Politics.

Technoscience, Organization and Material Culture (forthcoming with Duke University Press), a study of alternative interventions in technoscientific culture.

Website.

Contact details
Dr Dimitris Papadopoulos, University of Leicester, School of Management, University Road, Leicester LE1 7RH, UK. Email: d.papadopoulos@leicester.ac.uk

Tuesday, February 18, 2014

Trauma, PTSD, and Psychosis

http://www.amazon.com/gp/product/0470511737/ref=as_li_ss_tl?ie=UTF8&camp=1789&creative=390957&creativeASIN=0470511737&linkCode=as2&tag=integraloptio-20

I posted a briefer version of this on my Facebook page yesterday, but I wanted to add some more depth to it here. This is part of my preparation for a talk I will be giving to Tucson Police Department (TPD) detectives to help them better understand the experience of sexual trauma survivors.

One of the cool things about the book I cite from below is that it is re-confirming the connection between childhood trauma, dissociation, and psychosis - something that has been lost in recent decades as many researchers sought to find a genetic link for psychosis, or a clearly dysfunctional brain region.
Over the last several decades, evidence has accumulated that childhood trauma is common in persons who later develop schizophrenia or other psychotic disorders (Morrison, Frame and Larkin, 2003; Neria et al., 2002; see Chapter 10, this volume), and, in prospective studies, that childhood trauma is a significant risk factor for the development of subsequent psychotic disorders, even after controlling for potentially mediating variables, such as familial psychopathology (e.g. Janssen et al., 2004). Importantly, the Janssen et al. (2004) study of over 4000 individuals found a ‘dose–response’ relationship between childhood trauma and subsequent psychotic symptoms, with the most severely abused group demonstrating a 48 times increased risk compared to non-abused subjects.

[cited in "Delusional atmosphere, the psychotic prodrome and decontexualized memories," by Andrew Moskowitz, Lynn Nadel, Peter Watts and W. Jake Jacobs, page 68 - in Psychosis, Trauma and Dissociation: Emerging Perspectives on Severe Psychopathology; 2008]
Aside from a few clues that psychosis has a genetic underpinning, it has become clear that those genes are triggered into activation by childhood trauma. In fact, I suspect we still do not fully know what happens to the developing brain as a result of traumatic experiences.

We do know that trauma memories often play a role in psychosis, although because of the extreme dissociation involves in psychosis, it's often hard to make that connection.

This is one of the clearest explanations I have seen of why traumatic memories are (1) so much more deeply encoded, (2) so intrusive long after the original trauma, and (3) not likely to contain the level of detail (and reliability) law enforcement expects when interviewing a survivor:
"When memories are formed under intense stress, a critical component of normal memory formation – the hippocampus – is disabled, and memories without spatiotemporal content are created. At the same time, another component of normal memory function – the amygdala – can be potentiated, leading to stronger-than-usual memory for highly charged emotional events. When a person retrieves a traumatic event memory, the retrieved information is bereft of spatiotemporal context. Instead of being bound firmly to the past, this ‘disembodied’ event memory is conflated with the ongoing spatiotemporal frame. (Nadel and Jacobs, 1996: 459)"  (p. 66-67)
The trauma state is similar in some ways to infancy, the 3 earliest years before autobiographical memory comes online with the hippocampus.
Memories lacking spatiotemporal context occur not only under experiences of extreme stress, but also, Jacobs and Nadel (1985) contend, during the first few years of life, before the hippocampus becomes active. The limited functionality of the hippocampus has been argued to be a possible neurobiological foundation for so-called ‘infantile amnesia’ (Nadel and Zola-Morgan, 1984). Thus, ‘decontextualized’ affective memories occur when the hippocampus is disabled, under conditions of extreme stress during adulthood, and in the first few years of life when the hippocampus has not yet come ‘online’. In contrast, the amygdala, crucial for learning about danger situations, is functional from the beginning of life. (p. 67)
Here is an expansion of how all of this relates to the early stages of psychosis, the prodrome stage during which the continuity and logic of mental function begin to deteriorate.
In previous publications, Jacobs and Nadel have argued that several anxiety disorders could be understood as stemming from early childhood experiences – memories unlinked to an autobiographical, spatiotemporal nexus (Jacobs and Nadel, 1985, 1999; Nadel and Jacobs, 1996). While their models of PTSD, phobias and the first panic attack all presuppose exposure to a discrete triggering stimulus or stimuli at a particularly point in time, in order to adapt their model to the psychotic prodrome we have to allow for a different etiology – a slow, insidious reinstatement of early life experiences – that is, of ‘taxon-based’ instead of ‘locale-based’ learning.

Delusional atmosphere (DA) could be seen as even more consistent with ‘taxon-based’ learning than the anxiety disorders already modelled by Jacobs and Nadel because, in addition to evidence of high anxiety, there is in DA also evidence of disturbed visual perception and an inability to identify relevant and irrelevant stimuli consistent with early, feature-based memory. In addition, the characteristics of ‘taxon-based learning’ noted to be true for phobias – context independence, generalization and prolonged extinction (Jacobs and Nadel, 1985) – are equally true for delusions. Indeed, in many ways, DA sounds like the world of the infant as described by Nadel and Jacobs (1996), ‘populated not with the familiar objects and events of conscious adult life, but with fragments and features, pieces and patches’ (p. 460). These ‘fragments and features, pieces and patches’ do not disappear with adulthood, but instead lie just under surface of our awareness; they are a ‘veritable stew of impressions that we would scarce recognize’ if they popped into our conscious awareness (Nadel and Jacobs, 1996: 460). Is this what happens in DA?
We contend that these early experiences may be released in the psychotic prodrome as the functioning of the vulnerable hippocampi (smaller in size than is normal) is undermined by the stressful experiences (and exaggerated response to stressors) common in early schizophrenia. And, because such learning involves the connection between features of objects and threatening events (as in panic disorder), the actual trigger to the anxiety cannot be identified. Alternatively, later traumatic events could be ‘recalled’ without a spatiotemporal context, which is particularly likely in persons with autobiographical memory deficits, such as in schizophrenia. According to Nadel and Jacobs (1996), when this occurs, the ‘disembodied event memory is conflated to the ongoing spatio/temporal frame’ (p. 459). (p. 74)
One of the ways the mind can be damaged such that psychosis becomes a possibility is through attachment failures. Beyond the three organized forms of attachment (secure, avoidant, and ambivalent) there is also a disorganized attachment. Such an experience for the infant seem likely to stem from "memories unlinked to an autobiographical, spatiotemporal nexus."

From Chapter 9 in the same book, "An attachment perspective on schizophrenia: The role of
disorganized attachment, dissociation and mentalization," by Giovanni Liotti and Andrew Gumley, attachment patterns are explored as a possible cause for later psychosis.
Bowlby (1973) proposed that infants’ experience of interactions with attachment figures becomes internalized and is carried forward into childhood and adulthood as implicit core relational schemata, also known as internal working models (IWM; Bretherton and Munholland, 1999). These implicit structures produce expectations about the self and others, and regulate cognitive, behavioural and affective responses in interpersonal interactions. Early attachment relationships thus come to form, together with the intersubjective experiences of play and companionship with the caregivers (Trevarthen, 2005), the prototype for interpersonal relationships and self-regulation throughout life. Most interpersonal schemata that regulate relationships throughout childhood, adolescence and adulthood are influenced by the IWM of self and others developed in the interaction with the primary caregivers.

Infant attachment research has shown that, by twelve months, infants develop different organized patterns of attachment behaviour toward their caregivers, according to the responses they receive to their requests for comfort, soothing and protective closeness (Ainsworth et al., 1978). A specific IWM corresponds to each of these patterns. Three main patterns of early organized attachment have been identified: secure, avoidant and resistant (or ambivalent). In addition, a substantial minority of infants (around 15%; Van IJzendoorn, Schuengel and Bakermans-Kranenburg, 1999) fail to develop any organized or coherent attachment pattern; their attachments are said to be disorganized (Main, 1991).
Attachment theory explains the origins of disorganized attachment behaviour in terms of conflict between two different inborn systems, the attachment system and the fight–flight (i.e. defence) system. The attachment and defence systems normally operate in harmony (i.e. flight from the source of fear to find refuge near the attachment figure). They, however, clash in infant–caregiver interactions where the caregiver is at the same time the source of, and the solution for, the infant’s fear (Liotti, 2004). Being exposed to frequent interactions with a helplessly frightened, hostile and frightening, or confused caregiver, infants are caught in a relational trap; their defence system motivates them to flee from the frightened and/or frightening caregivers, while at the same time their attachment system motivates them, under the influence of separation fear, to approach them. Thus, the disorganized infant is bound to the experience of ‘fright without solution’ (Cassidy and Mohr, 2001; Main and Hesse, 1990: 163). This experience may be understood as a type of early relational trauma, which exerts an adverse influence on the development of the stress-coping system in the infant’s brain (Schore, 2003).
The damage caused by disorganized attachment has been linked the Axis II Borderline Personality Disorder (BPD) in a lot of research articles. More accurately, in my opinion, it is a form of complex post-traumatic stress disorder (C-PTSD).

It is entirely possible to live within this dissociated space from childhood. It's a form of "reenactment" because the person is continually reenacting the original trauma in the current context. I see this a LOT in the population we serve at SACASA, most of whom had childhood trauma.

Some survivors are reenacting traumas that occurred before autobiographical memory (and the hippocampus) came online around age 3, so there is no way for them to conceptualize, or even verbalize, that it is their early trauma that makes the world so scary or produces so much anxiety in them that they can barely function as adults. 

As the authors pointed out above, early traumatic events can be ‘recalled’ (or re-experienced) without a spatiotemporal context, which is particularly likely in persons with autobiographical memory deficits, such as in psychosis. Their trauma experience is "unstuck in time," continually being re-experienced with little or no awareness on their part of what is happening to them.

So for these people, being "unstuck in time" (love the Vonnegut reference here, since it is so apt to what he went through as a survivor of Dresden, which he describes in Slaughterhouse Five) is the norm, it is how they live every day, although they will not know that until they get into counseling or begin a serious meditation practice. 

We all do this to some degree, but it is usually transient and brief. If one of our childhood ego wounds gets triggered, we will react almost exactly as we did as children unless we have developed some awareness around the wounding and the reaction we learned as a coping strategy. The Internal Family Systems model (Richard Schwartz) and the Voice Dialogue model (Hal and Sidra Stone) both offer ways for those of us without severe trauma to work on these issues - and I generally consider "parts work" a deep form of shadow work. 

For those with this early wounding that leads to "psychotic" features in trauma survivors, shadow work is beyond their capacity. They need to be with a therapist who understands trauma and its effects on the brain and the sense of self.